Ask The Expert IDA Link New ADNI4
Contact Us

Previously Approved RARC Studies

Biofluid RARC-approved studies
Shipment DatePrincipal InvestigatorProjectTypeSpecimen NumberData Upload toADNI/LONI
Samples to be shippedDr. Stephen Pasternak, University of Western Ontario, Robarts Research Institute Brain Microparticle from Plasma: Non-Invasive “Brain Biopsies” for Improved Neurological DiagnosisPlasma755 plasmaSamples to be shipped
Jun, 2023Dr. Valerie Daggett, AltPep Corporation, University of WashingtonA Soluble Oligomer Binding Assay for Early Detection of Toxic Aβ Oligomers in Patients on the Alzheimer’s Disease ContinuumPlasma869 plasma from AD/MCI/HCQ3 or Q4 2024
Mar, 2023Dr. Patrick Oeckl, Research Group Leader at German Center for Neurodegenerative Diseases (DZNE), Dr. Markus Otto, Director of Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale)Longitudinal changes of the synaptic blood marker Beta-Synuclein in the ADNI cohort and relation to imaging and fluid biomarkersSerum300 CN, 300 MCI at baseline, 300 ADApr, 2024
Mar, 2022Paul Kinnon, DiamdemDiadem-Alzosure® Predict Clinical ValidationPlasma650 plasmaJul, 2022
Jan, 2023Dr. Hussein Yassine, University of Southern California, Dr. Dobrin Nedelkov, Isoformix, Dr. Wendy Mack, University of Southern California, Dr. Duke Han, University of Southern California, Dr. Meredith Braskie, University of Southern CaliforniaHDL particles and apoE glycosylation and lipid content in Alzheimer’s diseasePlasma188 plasma, 184 CSFSep, 2023
Dec, 2022FujirebioLumipulseG β-Amyloid Plasma 1-42, 1-40 and RatioPlasma130 plasmaJan, 2023
Feb, 2022Dr. Denise Selkoe, Brigham and Women's HospitalMechanism-based Plasma Biomarkers for AD diagnosis and prognosis (Plasma oAβ, Plasma NT1-tau)Plasma829 plasma from 275 HC, 379 MCI, 131 ADSep, 2023
Aug, 2021Dr. Michael Pontecorvo, Eli Lilly & Co, Dr. Ming Lu, Avid RadiopharmaceuticalsDiagnostic Performance Against the Brain PET Imaging Findings: Evaluation of a Novel Plasma ATN Biomarker Assay Plasma291 plasma from 279 unique participants plus 10 replicate samplesAnticipated Q4 2024
May, 2021Dr. Carlos Cruchaga, Washington UniversitysTREM2: CSF-derived miRNA’s as AD biomarkers in PlasmaPlasma367 Plasma 10 replicatesJun, 2023
Nov, 2020Dr. Julie Saugstad, Oregon Heath and Science UniversityCSF-derived miRNA’s as AD biomarkers in PlasmaPlasma & CSF80 Plasma, 80 matched CSF for HC 80 Plasma, 80 matched CSF for AD 5 CSF replicates, 5 plasma replicatesFeb, 2023
April, 2021Dr. Allan Levey, Emory UniversityCSF proteomeCSF719 CSFs matched to Rima K-D serum 10 replicatesJul, 2023
3nd Q 2020FNIH BC plasma Aβ study groupRound robin for plasma Aβ42/40; p-tau pilotPlasma130 ADNI GO/2 to each of 6 participating labsJune 2021; ptau Nov 2022 and updated Dec 2023
Nov, 2019Dr. Randall Bateman, Washington University School of MedicineAβ42/Aβ40 in CSF & plasmaCSF/Plasma638 plasma 487 CSFNov, 2022
Jul, 2018Dr. Robert Nagele, University of Medicine and Dentistry of New Jersey, Rowan University, Durin Technologies, Inc. (Autoantibody Array)Autoantibodies for AD detectionSerum406 ADNI1/GO/2 Baseline + Longitudinal Samples, 10 replicatesDate Uploaded: 12/18/2018
Mar, 2018Dr. William Hu, Emory University Center for Neurodegenerative DiseasesCSF Cytokines/Chemokines IACSF388 ADNIGO/2 Baseline + longitudinal Samples, 10 replicatesDate Uploaded: 1/04/2019
Jan, 2018FNIH BC/Caprion Proteome Inc., Washington DC/Montreal, Quebec, Canada {LC/MSMS}CMGA, NPTX2, VGF, CG2, FABP mrm/mass spectrometryCSF730 ADNI1, GO, 2 CSF Longitudinal Samples, 20 replicatesDate uploaded: April, 2019
Nov, 2017Dr. Randall Bateman, Washington University School of MedicineAb42/Ab40 in plasma of FBP+ / FBP- mrm/mass spectrometryPlasma200 ADNI GO/2 Baseline Plasma Samples, 20 replicates June, 2019
Oct /2017 for EI/FRB/MSD 9/2018 for S/SEuroimmune, Fujirebio MSD, Saladax/SiemensNew immunoassays for established AD biomarkersResidual CSFEI: 120 + 20 pool samples FRB: 422 + 20 pool samples MSD: 250 + 20 pool samples S/S: 373 + 20 pool samplesMSD 8/9/18 Euroimmune 4/19/19 FRB 3rd Q 2019
Sep, 2017Dr. Carlos Cruchaga, Washington University, and Marc Suarez-Calvert, DZNE, Germany {Immunoassays}sTREM2 & ProgranulinCSF1859 ADNI 1, GO, 2 BASELINE + Longtitudinal samplesData uploaded: 2/23/2018
Aug, 2017Dr. Henrik Zetterberg, Molndal, Sweden {Simoa}NFL & Tau diagnosis/prognosis p-tau181 addedPlasma3762 ADNI 1, GO, 2 longitudinal aliquot samples 20 replicatesNfL : 10/13/2018; p-tau181 uploaded 6/2020
May, 2017Dr. Jing Zhang, Harborview Medical Center, University of Washington School of Medicinea-Syn, Tau, Ab for AD Diagnosis Plasma310 ADNI 1, GO, 2 samples 10 replicatesData uploaded: 8/31/2020
Mar, 2017Dr. Dan Rader, Perelman School of Medicine, University of PennsylvaniaCholesterol effluxSerum795 ADNI 1 baseline samples 20 replicatesData uploaded: 2nd Q 2018
Jul, 2016Dr. Rima Kaddoura-Daouk, Duke University {multiple LC/MSMS}Metabolic networksSerum905* ADNIGO/2 BL samples 15 triplicates Each sub-aliquotted: 6,335 totalData uploaded: Throughout 2017
Sep, 2015Dr. Ian Sherriff, Araclon BiotechAβ1-42 and Aβ1-40 IAPlasma784 ADNI1, GO, 2 longitudinal aliquot samples 759 PLA aliquots 25 ReplicatesData uploaded: 2/16/2016
Mar, 2015Dr. Jing Zhang, Harborview Medical Center, University of Washington School of MedicineTotal α-syn, Ser129, Phosphorylated α-syn, IACSF*372 ADNI1 Baseline CSF aliquots samples      *transferred from Geoff Baird 461 ADNI1, GO, 2 longitudinal aliquot samples 446 CSFs 15 ReplicatesDate uploaded: Sept 2016
Sep, 2014Dr. Kaj Blennow, PI Clinical Neurochemistry LabTau Plasma High sensitivity IAPlasma595 ADNI1 aliquot samples 579 Baseline PLA 16 ReplicatesData uploaded: 8/4/2015
Jul, 2014Dr. Allan Levey, Emory University School of MedicineDDE** Mass spectrometryPlasma221 ADNI1 aliquot samples 211 Baseline PLA 10 replicatesData uploaded: 11/12/2014
May, 2014Dr. Kaj Blennow, PI Clinical Neurochemistry LabCerebrospinal fluid levels of neurogranin Neurofilament Light (NFL)CSF416 ADNI1 aliquot samples 400 Baseline CSFs 16 ReplicatesData uploaded: 8/20/2014
May, 2014Dr. Rima Kaddurah-Daouk, Duke UniversityMetabolic Pathways and Networks in Alzheimer’s Disease Mass spectrometrySerum833 ADNI1 aliquot samples 813 Baseline SER 20 ReplicatesData uploaded: 8/14/2015
Oct, 2013Dr. Courtney Sutphen, Washington University School of Medicine, Lab of Drs. Anne Fagan & David HoltzmanYKL-40 and VILIP-1 in Longitudinal CSF sample setsCSF612 ADNI1, GO, 2 longitudinal aliquot samples 597 CSFs 15 ReplicatesData uploaded: 7/15/2015
Sep, 2012PI: Dr. Lee Honigsberg, Genentech, co-Is: Dr. Nicholas Lewin-Koh, Genentech, Dr. Angus Nairn, Yale School of Medicine, Dr. Leslie Shaw, University of Pennsylvania, Dr. Dan Spellman, Merck Research Laboratories, Kristin Wildsmith, Genentech, Scientific Program Manager: Dr. Steve Hoffmann, The FNIH Biomarkers ConsortiumCSF proteomic study Caprion using mrm mass spectrometryCSF306 ADNI1 aliquot samples 290 Baseline CSFs 16 ReplicatesData uploaded: 4/04/2014
Sep, 2012Dr. Robert Nagele, University of Medicine and Dentistry of New Jersey, Rowan University, Durin Technologies, Inc. Autoantibody biomarkers for detection and diagnosis of Alzheimer’s diseaseSerum100 ADNI1 aliquot samples 50 Baseline MCI 50 Baseline NLData uploaded: 11/1/2012
May, 2012PI: Dr. Geoff Baird, University of Washington, co-Is: Dr. Thomas Montine, University of Washington, Elaine Peskind, University of WashingtonAnalyzing the CSF proteome with an oligonucleotideaptamer arrayCSF and Plasma727 ADNI1 aliquot samples 372 Baseline CSFs and matching 355 PLASamples forwarded to Jing Zhang, PI Ultimately, Data uploaded: 9/21/2016
Jan, 2012PI: Dr. Lee Honigsberg, Genentech, co-Is: Dr. Nicholas Lewin-Koh, Genentech, Dr. Angus Nairn, Yale School of Medicine, Dr. Leslie Shaw, University of Pennsylvania, Dr. Dan Spellman, Merck Research Laboratories, Kristin Wildsmith, Genentech, Scientific Program Manager: Dr. Steve Hoffmann, The FNIH Biomarkers ConsortiumPilot Study CSF proteomics project Caprion using mrm mass spectrometry* PPSB ProteomicsCSF25 ADNI1 aliquot samples 20 Baseline CSFs: 10 AD, 10 NL and 5 aliquots of a CSF poolData uploaded: 4/04/2014 with the main mrm MSMS Proteomic Study
Sep, 2011PI: Dr. Mary Savage, Merck Research Laboratories, co-I: Dr. Dan Holder, Merck Research Laboratories, Scientific Program Manager: Dr. Judy Siuciak, the FNIH Biomarkers ConsortiumBACE and sAPP in CSF CSF402 ADNI1 aliquot samples 382 Baseline CSF 20 ReplicatesData uploaded: 4/24/2012
Aug, 2011PI: Dr. William Potter, FNIH Biomarker Consortium co-Is: Dr. Eve Pickering, Pfizer, Dr. Mitch Kling, University of Pennsylvania, Dr. Leslie Shaw, University of Pennsylvania, Dr. Fred Immerman, Scientific Program Manager: Dr. Judy Siuciak, The FNIH Biomarkers ConsortiumCSF proteomic study RBM* PPSB Proteomic studiesCSF317 ADNI1 aliquot samples 311 Baseline CSFs 16 ReplicatesData uploaded: 01/03/2012
Mar, 2011Dr. Jing Zhang, Harborview Medical Center University of Washington School of MedicineADNI RARC CSF Proteomic studyCSF390 ADNI1 aliquot samples Baseline CSFs: 92 AD, 187 MCI, 111 NCData uploaded: 3/11/2013
May-20102010-2011: PI: Dr. Holly Soares (2010-2011), Pfizer, Statistical analyses: Dr. Eve Pickering, Pfizer, Dr. Fred Immerman, Pfizer, co-Is: Dr. William Potter, FNIH Biomarker Consortium, Dr. Max Kuhn, Pfizer, Dr. David Shera, Merck, Dr. Mats Ferm, AstraZenecat, Robert Dean, Eli Lilly, Adam Simon, Merck, Frank Swenson, Pfizer, Judy Siuciak, FNIH Biomarkers Consortium, June Kaplow, Eisai Medical Research, Madhay Thambisetty, NIA, Panayiotis Zagouras, Pfizer, Walter Koroshetz, National Institute of Neurological Disorders and Stroke, Hong Wan, Pfizer, John Trojanowski, University of Pennsylvania, Leslie M Shaw, University of Pennsylvania; Scientific Program Managers: Dr. David Lee, FNIH Biomarkers Consortium, and Dr. Judy Siuciak, FNIH Biomarkers Consortium 2011-2013: PI: Dr. William Potter, FNIH Biomarker Consortium, co-Is: Dr. Eve Pickering, Pfizer, Dr. Fred Immerman, Pfizer; Statistical analyses: Dr. Mitch Kling, University of PennsylvaniaPlasma proteomic study Rules Based Medicine (RBM)* PPSB Proteomic studies1065 ADNI1 aliquot samples Baseline PLA: 394 MCI, 111 AD, 57 NL Year 1 PLA: 349 MCI, 98 AD, 56 NL 317 ADNI1 aliquot samples 311 Baseline CSFs 16 Replicates11/1/2010
Mar-2010Dr. John McIntyre, St. Francis HospitalRedox Reactive Autoantibodies in ADNI subjects RARC/study phase 2Serum90 ADNI1 aliquot samples Baseline SER: 30 NC, 30 MCI and 30 ADData uploaded: 07/21/2011
Jul-2009Dr. John McIntyre, St. Francis HospitalRedox Reactive Autoantibodies in ADNI subjects, RARC/study phase 1Serum18 ADNI1 aliquot samples Baseline SER: 6 NC, 6 MCI and 6 ADData uploaded: 11/29/2009
Jul-2009Dr. Lucas Restrepo, David Geffen School of Medicine at UCLAImmuno signature of Alzheimer’s Disease: using a blood plasma testPlasma100 ADNI1 aliquot samples Baseline PLA: 50 AD & 50 NLStudy not completed
Dec-2007Dr. Andy Saykin, Indiana University, Dr. Dietrich Stephan, Indiana University, Dr. Steven Potkin, UC IrvineWhole genome analysis of ADNI1 cohort following DNA extraction(at Cogenics) Genetic association analysis of the ADNI 1 cohortWhole blood807 ADNI1 aliquot samples ADNI 1 Screening/Visit1 ApoE residual samplesData uploaded: 3/16/2009
Genetics RARC (BRC)-Approved Studies
Shipment DatePrincipal InvestigatorProjectTypeSpecimen Number
5/7/2008Alison Goate, Washington UniversityAttempt to replicate genetic associations observed between CSF biomarker and neuroimaging phenotypes in samples collected at Washington UniversityDNA803
8/11/2010Keoni Kauwe, Brigham Young UniversitymtGCN phenotyping and ADNI phenotype data to examine the association between mtGCN and dementia and other phenotypes of interestDNA806
10/18/2011Carlos Cruchaga, Washington UniversityMolecular testing to look for APP mutationDNA2
1/17/2012Matthew Blurton-Jones, UC Irvine"Proof of concept" to demonstrate measurements of mitochondrial function and has relevance for clinical diagnosis of ADCell Line20
10/8/2013Holly Soares, Bristol-Myers Squibb CompanyRNA expression profiling to understand association of transcript profilesWhole Blood811
5/7/2014Zoran Brkanac, University of WashingtonSequence candidate genes for association with ADDNA576
12/1/2014Carlos Cruchaga, Washington UniversityIdentifying of risk and protective variants, using WGS and specific APOE genotypesDNA808
8/29/2016AbbvieMethylation ProjectDNA1919
8/29/2016AbbvieTelomere ProjectDNA1919
8/29/2016Laura P.W. Ranum, University of FloridaMethylation ProjectDNA1
8/29/2016Laura P.W. Ranum, University of FloridaTelomere ProjectDNA1
11/7/2016Jue Lin, University of California San FranciscoMethylation ProjectDNA1920
11/7/2016Jue Lin, University of California San FranciscoTelomere ProjectDNA1920
7/31/2017Matthew Huentelman, TgenValidating results with WES using different technologyDNA22
2/19/2018Julie Rutten, Leiden UniversityConfirmation of a variantDNA1
11/13/2018Jerry Schellenberg, University of PennsylvaniaConfirmation of variant finding in ADSPDNA1
4/23/2019Jerry Schellenberg, University of PennsylvaniaSV in genes that could increase or decrease risk for ADDNA7
12/21/2020Jerry Schellenberg, University of PennsylvaniaConfirmation of finding from ADSP dataDNA1
1/21/2021Bruno Vellas, Toulouse University HospitalRBCs for the ADNI-3 studyRBC849
11/16/2021Mark Ebbert, University of KentuckyExtracted DNA for long read sequencing to look for a specific rare variantCell Line1
2024 Alzheimer’s Disease Neuroimaging Initiative
This website is funded by the Alzheimer’s Disease Neuroimaging Initiative